Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | ABCC9 | O60706 | 2/20 | 0.40 |
| ▸ | ABCC8 | Q09428 | 2/20 | 0.40 |
| ▸ | KCNJ11 | Q14654 | 2/20 | 0.40 |
| ▸ | KCNJ8 | Q15842 | 2/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.34 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | NAMPT | P43490 | 3/20 | 0.34 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19668355 | 1.00 | P2RX7 (0.43) | P2RX7KMT2AMEN1ABCC9ABCC8 | |
| SCHEMBL16994510 | 0.87 | P2RX7 (0.44) | P2RX7KMT2AMEN1ABCC9ABCC8 | |
| SCHEMBL9902361 | 0.87 | P2RX7 (0.44) | P2RX7KMT2AMEN1ABCC9ABCC8 | |
| SCHEMBL9902357 | 0.87 | P2RX7 (0.44) | P2RX7KMT2AMEN1ABCC9ABCC8 | |
| SCHEMBL9905806 | 0.87 | P2RX7 (0.39) | P2RX7KMT2AABCC9KCNJ11CYP1A2 | |
| SCHEMBL9905805 | 0.87 | P2RX7 (0.39) | P2RX7KMT2AABCC9KCNJ11CYP1A2 | |
| SCHEMBL16994500 | 0.87 | P2RX7 (0.39) | P2RX7KMT2AABCC9KCNJ11CYP1A2 | |
| SCHEMBL17271378 | 0.87 | P2RX7 (0.39) | P2RX7KMT2AMEN1ABCC9KCNJ11 | |
| SCHEMBL16994512 | 0.87 | P2RX7 (0.39) | P2RX7KMT2AMEN1ABCC9KCNJ11 | |
| SCHEMBL16994511 | 0.83 | P2RX7 (0.41) | P2RX7KMT2AMEN1ABCC9ABCC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2017208129-A1 | PHARMACEUTICAL COMPOSITION AND METHOD FOR REDUCING INTRAOCULAR PRESSURE | TISBURY PHARMACEUTICALS, INC. (US) | 2017-12-07 | — | — | WO | disclosed |
| US-20170107198-A1 | MULTIFUNCTIONAL NITROXIDE DERIVATIVES AND USES THEREOF | TISBURY PHARMACEUTICALS, INC | 2017-04-20 | — | — | US | disclosed |
| US-9522903-B2 | Multifunctional nitroxide derivatives and uses thereof | RADIKAL THERAPEUTICS INC. (US) | 2016-12-20 | — | — | US | disclosed |
| US-20150336932-A1 | MULTIFUNCTIONAL NITROXIDE DERIVATIVES AND USES THEREOF | TISBURY PHARMACEUTICALS, INC | 2015-11-26 | — | — | US | disclosed |
| US-9102659-B2 | Multifunctional nitroxide derivatives and uses thereof | RADIKAL THERAPEUTICS INC. (US) | 2015-08-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170107198-A1 | MULTIFUNCTIONAL NITROXIDE DERIVATIVES AND USES THEREOF | NOX4, NOX1, NOS1 | P2RX7 348/4885KMT2A 3054/4885MEN1 4442/4885 |
| US-20150336932-A1 | MULTIFUNCTIONAL NITROXIDE DERIVATIVES AND USES THEREOF | NOX4, NOX1, NOX3 | P2RX7 412/4885KMT2A 3506/4885MEN1 4636/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.